Physician profile
Ibrahim J Raphael
NPI 1275943144
$12,977.14
in general payments reported to CMS, 2019-2025
27 companies · $8,066 in 2025
The $8,066 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,817 · 2020: $320 · 2021: $211 · 2022: $293 · 2023: $2,174 · 2024: $95.87 · 2025: $8,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $2,394 · Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $2,393.94 |
| Food and Beverage | $942.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,943.84 | 2025 | |
| Inari Medical, INC. | $2,322.09 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Becton, Dickinson and Company | $492.67 | 2019 | |
| Allergan, INC. | $289.60 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $252.07 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.99 | 2019-2021 | |
| Inspire Medical Systems, INC. | $176.37 | 2021-2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $175.04 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $153.35 | 2019 | |
| United Therapeutics Corporation | $150.55 | 2019-2022 | |
| Pulmonx Corporation | $121.87 | 2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $103.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $70.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.51 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $59.92 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $58.93 | 2019 | |
| Vifor Pharma, INC. | $53.74 | 2019 | |
| Paratek Pharmaceuticals, INC. | $53.25 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $46.12 | 2020 | |
| Glaxosmithkline, LLC. | $44.10 | 2019 | |
| Gilead Sciences, INC. | $29.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.12 | 2019 | |
| Chiesi USA, INC. | $19.35 | 2019 | |
| Genzyme Corporation | $18.69 | 2023 | |
| Edwards Lifesciences Corporation | $18.22 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.24 | 2019 | |
| Electromed, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.